Chronic Myeloid Leukemia (BCR-ABL1) · line 2 · Ponatinib for CML T315I+ OR post ≥2 TKI failure
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-PONATINIB-CML |
| ID | IND-CML-2L-PONATINIB-T315I |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CML |
| Sources | SRC-ELN-CML-2020 SRC-NCCN-MPN-2025 SRC-PACE-CORTES-2013 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for T315I+ OR post-multi-TKI CML. Vascular toxicity profile dominant safety concern. Asciminib 200 mg BID is alternative for T315I; ponatinib retains broader experience + responsive even at reduced dose. Ukraine access barrier.
Used By
Algorithms
ALGO-CML-2L- ALGO-CML-2L